Biomarkers and Precision Medicine, in Plain Words

Part of Understanding Cancer Trials: Eligibility and biomarkers.

About 3 minutes. Free, in your language, no account needed.

This is general education about clinical research — not medical advice, and not a way to join a study. Talk to your own doctor about your situation.

You may hear the words biomarker, molecular testing, genomic profiling, targeted therapy, or precision medicine. They are related ideas, and none of them is as complicated as it sounds.

What a biomarker is

A biomarker is something measurable in the body that carries information.

It might be a protein on the surface of tumor cells. It might be a change in a gene inside the tumor. It might be something measured in blood. What makes it a biomarker is not what it is made of, but that measuring it tells someone something useful.

What biomarkers are used for

Different biomarkers do different jobs, and mixing them up causes confusion.

• Diagnostic — helps identify what a disease is.
• Prognostic — carries information about how a disease is likely to behave, regardless of treatment.
• Predictive — carries information about whether a particular treatment is likely to act on that disease.

The third kind is the one behind targeted treatment. If a tumor has a specific feature, and a treatment is designed to act on that feature, then the feature predicts whether the treatment has something to act on.

Where "precision medicine" comes from

For a long time, cancer treatment was chosen mainly by where the cancer started and how far it had spread.

Better laboratory testing made it possible to look at features inside the tumor itself. Two cancers that started in the same organ may have very different features, and two that started in different organs may share one.

Precision medicine is the general name for choosing treatment using those features rather than location alone. In research, it has changed how studies are designed. Some studies now enroll people based on a shared tumor feature across several different cancer types.

What biomarkers have to do with eligibility

This is the practical connection.

Many cancer studies now require a specific biomarker to be present, because the treatment being tested was designed around it. If a tumor does not have that feature, the treatment has nothing to act on. Not meeting a biomarker criterion is one of the most common reasons a person is not eligible for a particular study.

That is a fact about the biology of one tumor and the design of one study. The previous lesson applies here in full.

Honest limits

Biomarker testing is genuinely useful, and it is genuinely limited. Both are true.

• Not every cancer has a known targetable feature. Many do not.
• A predictive biomarker shifts the odds. It does not guarantee an outcome.
• Testing takes time, sometimes several weeks, and needs enough tissue or a suitable blood sample.
• Availability is unequal. Some tests are routine in some health systems and unavailable in others.

If molecular testing is discussed in your own care, reasonable things to ask are what test is being done, what it is looking for, how long the result will take, what will be done with the tissue or sample, and what the result would and would not tell anyone.

In short

• A biomarker is something measurable in the body that carries useful information.
• Predictive biomarkers say whether a treatment has something to act on. That is the basis of targeted treatment.
• Precision medicine means choosing treatment by features of the disease rather than location alone.
• A required biomarker is a common eligibility criterion, and not having it is a fact about biology, not about you.
• Biomarker testing is useful, takes time, is not available everywhere, and shifts odds rather than guaranteeing outcomes.